Skip to main content

Table 1 Patient demographic characteristics

From: Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

Group Parameter   (Sitagliptin only) +Sitagliptin (combination therapy)
Overall Diet/exercise therapy Low-dose glimepiride (0.5–1.0 mg) Medium-dose glimepiride (1.5–2.0 mg) Biguanide Thiazolidine α-GI Coadministration of two or more drugs
n 651 189 72 50 99 38 18 185
Age (y) 63.8 ± 11.8 64.6 ± 12.7 68.1 ± 11.1 65.3 ± 11.2 59.3 ± 11.4 64.3 ± 12.2 63.9 ± 11.7 63.2 ± 10.8
Sex (male %) 434 (66.7) 121 (64.0) 44 (61.1) 37 (74.0) 72 (72.7) 27 (71.1) 13 (72.2) 120 (64.9)
BMI (kg/m2) 25.2 ± 4.2 24.5 ± 4.1 24.3 ± 4.0 24.5 ± 3.5 25.8 ± 3.6 26.4 ± 7.1 25.9 ± 3.9 25.7 ± 4.1
Abdominal circumference (cm) 88.3 ± 11.1 87.3 ± 10.7 88.7 ± 10.7 85.1 ± 8.2 88.9 ± 9.0 92.9 ± 21.4 92.4 ± 7.2 87.9 ± 10.1
Disease duration (y) 8.8 ± 6.7 6.2 ± 5.7 8.2 ± 6.4 10.2 ± 8.1 9.4 ± 6.8 10.5 ± 7.1 8.7 ± 5.7 10.5 ± 6.5
Smoking habit (%) 143 (22.7) 32 (17.4) 14 (20.3) 16 (34.0) 26 (27.1) 5 (13.5) 4 (22.2) 46 (25.6)
Drinking habit (%) 301 (48.1) 79 (42.5) 31 (47.0) 33 (68.8) 51 (53.1) 19 (52.8) 10 (55.6) 78 (44.3)
HbA1c (%) 7.86 ± 1.07 7.67 ± 1.09 7.74 ± 0.86 8.23 ± 1.31 8.05 ± 1.10 7.64 ± 0.74 7.26 ± 0.76 8.00 ± 1.04
Converted mean HbA1c (mmol/mol) 62 60 61 66 64 60 56 64
Fasting blood glucose (mg/dL) 159.2 ± 41.5 152.7 ± 43.5 156.6 ± 35.4 166.5 ± 38.7 173.5 ± 48.1 154.1 ± 38.3 146.0 ± 43.3 158.9 ± 36.5
HOMA-IR 2.83 ± 1.80 2.36 ± 1.45 2.70 ± 1.69 2.97 ± 1.92 3.34 ± 1.72 2.68 ± 2.03 2.69 ± 1.75 3.01 ± 2.03
HOMA-β (%) 32.1 ± 27.1 32.6 ± 33.9 29.4 ± 20.1 33.4 ± 25.7 31.5 ± 22.7 29.1 ± 21.3 36.0 ± 35.2 33.0 ± 25.3
C-Peptide (ng/mL) 2.10 ± 0.89 2.10 ± 0.90 2.36 ± 1.64 2.08 ± 0.58 2.14 ± 0.74 1.97 ± 0.78 2.00 ± 0.74 2.05 ± 0.96
SBP (mmHg) 130.9 ± 14.9 128.9 ± 16.1 134.0 ± 13.4 131.8 ± 11.4 131.0 ± 16.5 131.6 ± 16.3 130.5 ± 13.4 131.4 ± 13.8
DBP (mmHg) 76.5 ± 10.5 75.7 ± 9.7 76.5 ± 9.5 77.3 ± 10.3 79.6 ± 11.9 76.8 ± 11.4 79.7 ± 12.0 75.1 ± 10.2
Hypertension 393 (60.4) 107 (56.6) 46 (63.9) 29 (58) 60 (60.6) 24 (63.2) 13 (72.2) 114 (61.6)
Dyslipidemia 417 (64.1) 102 (54) 41 (56.9) 34 (68) 72 (72.7) 25 (65.8) 12 (66.7) 131 (70.8)
Hyperuricemia 65 (10) 17 (9) 4 (5.6) 2 (4) 13 (13.1) 5 (13.2) 7 (38.9) 17 (9.2)
Retinopathy 48 (7.4) 7 (3.7) 3 (4.2) 2 (4) 18 (18.2) 1 (2.6) 3 (16.7) 14 (7.6)
Arteriosclerosis obliterans 55 (8.4) 8 (4.2) 2 (2.8) 2 (4) 25 (25.3) 2 (5.3) 2 (11.1) 14 (7.6)
Atrial fibrillation 16 (2.5) 5 (2.6) 2 (2.8) 2 (4) 2 (2) 1 (2.6) 0 (0) 4 (2.2)
Renal disease 49 (7.5) 5 (2.6) 2 (2.8) 2 (4) 16 (16.2) 3 (7.9) 4 (22.2) 17 (9.2)
Hepatic disease 56 (8.6) 15 (7.9) 3 (4.2) 4 (8) 14 (14.1) 4 (10.5) 3 (16.7) 13 (7)
Myocardial infarction 18 (2.8) 5 (2.6) 2 (2.8) 1 (2) 3 (3) 0 (0) 2 (11.1) 5 (2.7)
Cerebral stroke 45 (6.9) 8 (4.2) 4 (5.6) 3 (6) 6 (6.1) 3 (7.9) 4 (22.2) 17 (9.2)
Angina pectoris 27 (4.1) 9 (4.8) 2 (2.8) 3 (6) 6 (6.1) 1 (2.6) 1 (5.6) 5 (2.7)
Cardiac failure 11 (1.7) 3 (1.6) 3 (4.2) 1 (2) 1 (1) 0 (0) 0 (0) 3 (1.6)
  1. Data presented as n (%) or mean ± SD